Volume 377, Issue 9779, Pages (May 2011)

Slides:

Advertisements

Similar presentations

Volume 14, Issue 12, Pages (November 2013)

Advertisements

Volume 370, Issue 9586, Pages (August 2007)

Volume 14, Issue 4, Pages (April 2013)

Volume 385, Issue 9980, Pages (May 2015)

Volume 389, Issue 10072, Pages (March 2017)

Volume 16, Issue 2, Pages (February 2015)

Volume 367, Issue 9517, Pages (April 2006)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 388, Issue 10058, Pages (November 2016)

Volume 15, Issue 6, Pages (May 2014)

Volume 378, Issue 9809, Pages (December 2011)

Volume 5, Issue 4, Pages (April 2006)

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 373, Issue 9666, Pages (March 2009)

Volume 389, Issue 10076, Pages (April 2017)

Volume 13, Issue 3, Pages (March 2012)

Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study Matthew Waxman, MD,

Volume 376, Issue 9757, Pages (December 2010)

Volume 374, Issue 9707, Pages (December 2009)

Volume 373, Issue 9663, Pages (February 2009)

Volume 14, Issue 7, Pages (June 2013)

Volume 378, Issue 9786, Pages (July 2011)

Volume 15, Issue 4, Pages (April 2014)

Volume 14, Issue 8, Pages (July 2013)

Volume 14, Issue 8, Pages (July 2013)

Volume 12, Issue 7, Pages (July 2011)

Volume 379, Issue 9812, Pages (January 2012)

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.

Volume 387, Issue 10023, Pages (March 2016)

Volume 389, Issue 10073, Pages (March 2017)

Volume 14, Issue 6, Pages (May 2013)

Volume 14, Issue 11, Pages (October 2013)

Volume 373, Issue 9666, Pages (March 2009)

Volume 18, Issue 3, Pages (March 2017)

Volume 385, Issue 9962, Pages (January 2015)

Volume 19, Issue 4, Pages (April 2018)

Volume 15, Issue 8, Pages (July 2014)

Volume 371, Issue 9625, Pages (May 2008)

Volume 388, Issue 10058, Pages (November 2016)

Volume 371, Issue 9627, Pages (May 2008)

Volume 9, Issue 4, Pages (April 2008)

Volume 388, Issue 10055, Pages (October 2016)

Volume 15, Issue 6, Pages (May 2014)

Volume 392, Issue 10162, Pages (December 2018)

Volume 14, Issue 6, Pages (May 2013)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile):

Volume 5, Issue 4, Pages (April 2018)

Volume 375, Issue 9726, Pages (May 2010)

Volume 16, Issue 8, Pages (August 2015)

Volume 373, Issue 9658, Pages (January 2009)

Volume 378, Issue 9809, Pages (December 2011)

Volume 14, Issue 8, Pages (July 2013)

Volume 373, Issue 9658, Pages (January 2009)

Volume 375, Issue 9714, Pages (February 2010)

Volume 15, Issue 6, Pages (May 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 15, Issue 8, Pages (July 2014)

Volume 11, Issue 3, Pages (March 2010)

Volume 376, Issue 9757, Pages (December 2010)

Volume 371, Issue 9618, Pages (March 2008)

Volume 375, Issue 9715, Pages (February 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 13, Issue 5, Pages (May 2012)

Volume 368, Issue 9541, Pages (September 2006)

Volume 14, Issue 7, Pages (June 2013)

Volume 371, Issue 9617, Pages (March 2008)

Volume 392, Issue 10162, Pages (December 2018)

Presentation transcript:

Volume 377, Issue 9779, Pages 1749-1759 (May 2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial Prof Matthew T Seymour, MD, Lindsay C Thompson, MSc, Prof Harpreet S Wasan, MD, Gary Middleton, MD, Alison E Brewster, MD, Stephen F Shepherd, MD, M Sinead O'Mahony, MBBS, Prof Timothy S Maughan, MD, Prof Mahesh Parmar, DPhil, Ruth E Langley, PhD The Lancet Volume 377, Issue 9779, Pages 1749-1759 (May 2011) DOI: 10.1016/S0140-6736(11)60399-1 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile FU=simplified LV5FU2 regimen of levofolinate, bolus fluorouracil, and 46-h infusion of fluorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap. OxFp=oxaliplatin plus fluoropyrimidine (either fluorouracil or capecitabine). The Lancet 2011 377, 1749-1759DOI: (10.1016/S0140-6736(11)60399-1) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier curves for PFS and OS for each main effect comparison and hazard ratio plots to show tests for heterogeneity for each factorial comparison (A) PFS by addition of oxaliplatin. (B) PFS by FU versus Cap. (C) OS by addition of oxaliplatin. (D) OS by FU versus Cap. PFS=progression-free survival. OS=overall survival. FU=simplified LV5FU2 regimen of levofolinate, bolus fluorouracil, and 46-h infusion of fluorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap. The Lancet 2011 377, 1749-1759DOI: (10.1016/S0140-6736(11)60399-1) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 Association of categorical factors (A) and continuous factors (B) associated with OTU outcome Odds of a worse outcome is expressed with reference to the more normal state, or as an odds ratio proportional across all categories. OTU=overall treatment utility. WBC=white blood cell. GFR=glomerular filtration rate. BMI=body-mass index. FU=simplified LV5FU2 regimen of levofolinate, bolus fluorouracil, and 46-h infusion of fluorouracil, repeated every 2 weeks. Ox=oxaliplatin. Cap=capecitabine. ADL=activities of daily living. *Mean EORTC QLQ-C30 symptom score. †Calculated as 100/time in s to walk 20 m. The Lancet 2011 377, 1749-1759DOI: (10.1016/S0140-6736(11)60399-1) Copyright © 2011 Elsevier Ltd Terms and Conditions